AIM Concept Integration
3rd Year MBBS
CVS Module
3rd Year MBBS
CVS Module
“`
Arrhythmias, Myocarditis, Pericardial Disease and Antiarrhythmic Therapy
Connect abnormal cardiac electrical activity and inflammation with ECG findings, clinical instability, treatment priorities and major complications for rapid revision.
“`
“`
1. The Topic in One Connected Flow
Arrhythmias develop when cardiac impulse formation or conduction becomes abnormal. Ischemia, structural disease, metabolic disturbance, inflammation or drugs may disturb ion movement and create abnormal automaticity, triggered activity, re-entry or conduction block. Myocardial and pericardial inflammation can also reduce contraction or ventricular filling.
Trigger
Ischemia, scar, electrolyte imbalance, thyroid excess, infection, inflammation or drug toxicity
→
Core Mechanism
Altered Na⁺, Ca²⁺ or K⁺ movement → automaticity, afterdepolarization, re-entry or conduction delay
→
Cardiac Change
Atrial fibrillation, ventricular tachyarrhythmia, AV block, impaired contraction or restricted ventricular filling
→
Clinical Effect
Palpitations, breathlessness, chest pain, dizziness, syncope, heart failure or cardiac arrest
→
Diagnostic Clue
ECG pattern linked with stability, electrolytes, troponin and echocardiographic findings
→
Action
Assess stability → control or terminate rhythm → correct the underlying cause → prevent recurrence or embolism
→
Outcome
Preserved cardiac output with reduced stroke, heart failure and sudden-death risk
Electrical pathway
Abnormal impulse formation or conduction → atrial fibrillation, ventricular tachycardia, torsades or heart block → reduced filling or output → instability, embolism or sudden cardiac death.
Inflammatory pathway
Myocardial inflammation → myocyte injury, reduced contractility and electrical instability. Pericardial inflammation → positional pain and effusion → rising pressure may impair ventricular filling and cause tamponade.
2. Key Clinical Connections
Atrial Fibrillation and Stroke
Disorganized atrial activity → absent effective atrial contraction → left atrial appendage stasis → thrombus and embolic stroke risk.
Absent organized P waves with irregular R–R intervals → supports atrial fibrillation → rate or rhythm control must be combined with anticoagulation assessment.
Ventricular Tachyarrhythmia
Previous myocardial infarction and ventricular scar → re-entry circuit → regular broad-complex ventricular tachycardia → reduced output or sudden deterioration.
Unstable VT with a pulse → synchronized cardioversion; pulseless VT or VF → defibrillation and CPR.
QT Prolongation and Torsades
Class IA or III drug with K⁺ or Mg²⁺ depletion → delayed ventricular repolarization → prolonged QT and early afterdepolarizations → polymorphic VT.
Torsades de pointes → stop the causative drug, correct electrolytes and give intravenous magnesium.
Myocardial and Pericardial Inflammation
Recent infection → myocardial injury and electrical instability → troponin elevation, ventricular dysfunction, arrhythmia or heart block → myocarditis.
Positional pleuritic pain with rub and diffuse ECG changes → pericarditis; effusion with hypotension, raised JVP and chamber collapse → tamponade requiring urgent drainage.
3. AIM High-Yield Integration Review
⭐ Atrial fibrillation → absent organized P waves and irregularly irregular ventricular rhythm → ineffective atrial contraction and thromboembolic stroke risk.
Rate control in atrial fibrillation → slows ventricular response and improves symptoms → does not remove atrial stasis or the need to assess anticoagulation.
⭐ Broad-complex tachycardia with structural heart disease → likely ventricular tachycardia → assess hemodynamic stability before choosing electrical or drug treatment.
⭐ Pulseless VT or ventricular fibrillation → no effective cardiac output → defibrillation and CPR rather than synchronized cardioversion.
Class I drugs block Na⁺ channels, Class II reduces nodal automaticity, Class III prolongs repolarization and Class IV slows Ca²⁺-dependent AV nodal conduction.
⭐ Prolonged QT with polymorphic VT → torsades de pointes → withdraw the causative drug, correct K⁺ and Mg²⁺ and give intravenous magnesium.
Flecainide in structural or ischemic heart disease → excessive conduction slowing and proarrhythmia → potentially dangerous ventricular rhythm.
Myocarditis or tamponade with instability → impaired contraction or filling → urgent specialist management to prevent heart failure, shock, malignant arrhythmia or death.
AIM Exam Trap: Do not treat the ECG pattern in isolation. First determine whether the patient is stable, then identify and correct structural, inflammatory, metabolic or drug-related causes.
“`